Indeed, our results showed significant positive correlations for CML with serum levels of sclerostin and FGF23, both of which secreted by osteocytes to impair bone mineralization. This evidence concerns the gene FGF23 and chronic myelogenous leukemia, BCR-ABL1 positive.